Arjun Agarwal Sells 10,290 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $59.07, for a total value of $607,830.30. Following the transaction, the senior vice president directly owned 16,406 shares of the company’s stock, valued at $969,102.42. The trade was a 38.55% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arjun Agarwal also recently made the following trade(s):

• On Monday, March 16th, Arjun Agarwal sold 395 shares of Oruka Therapeutics stock. The shares were sold at an average price of $41.30, for a total value of $16,313.50.

Oruka Therapeutics Price Performance

ORKA stock traded down $3.59 during mid-day trading on Monday, reaching $58.34. 1,905,934 shares of the company traded hands, compared to its average volume of 1,049,294. The company has a market capitalization of $3.52 billion, a P/E ratio of -30.07 and a beta of -0.20. Oruka Therapeutics, Inc. has a 52-week low of $9.54 and a 52-week high of $91.00. The company has a fifty day moving average price of $55.17 and a 200-day moving average price of $39.42.

Oruka Therapeutics (NASDAQ:ORKA) last posted its earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.04. As a group, analysts forecast that Oruka Therapeutics, Inc. will post -2.15 EPS for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on ORKA shares. UBS Group upped their target price on Oruka Therapeutics from $75.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, April 28th. HC Wainwright reaffirmed a “buy” rating and issued a $120.00 target price on shares of Oruka Therapeutics in a research note on Monday. Barclays upped their target price on Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a research note on Monday, April 27th. Wedbush set a $165.00 target price on Oruka Therapeutics in a research note on Monday, April 27th. Finally, BTIG Research reiterated a “buy” rating and issued a $151.00 price objective on shares of Oruka Therapeutics in a research report on Thursday. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $120.80.

Institutional Trading of Oruka Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ORKA. Goldman Sachs Group Inc. bought a new stake in Oruka Therapeutics in the first quarter valued at approximately $2,505,000. JPMorgan Chase & Co. lifted its position in Oruka Therapeutics by 567.7% in the second quarter. JPMorgan Chase & Co. now owns 15,425 shares of the company’s stock valued at $173,000 after purchasing an additional 13,115 shares during the last quarter. Legal & General Group Plc bought a new position in shares of Oruka Therapeutics during the second quarter valued at approximately $28,000. Rhumbline Advisers bought a new position in shares of Oruka Therapeutics during the second quarter valued at approximately $320,000. Finally, New York State Common Retirement Fund bought a new position in shares of Oruka Therapeutics during the second quarter valued at approximately $96,000. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.